The newest tool in the fight against oral disease is the ViziLite Plus oral lesion identification and marking system.
ViziLite Plus, from Zila Pharmaceuticals, combines the oral screening technology of ViziLite, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630. TBlue630 is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a ViziLite examination.
ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If ViziLite reveals an abnormality, TBlue630 can be used to mark suspicious lesions for further evaluation.
